Ultragenyx Pharmaceutical INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Ultragenyx Pharmaceuticals Inc. announces its 2025 Annual Meeting and provides details on proposals for stockholder voting, including director nominations, incentive plan approval, auditor ratification, and executive compensation.
NASDAQ
Ultragenyx Pharmaceutical Inc. has released its proxy statement detailing proposals for the upcoming annual stockholders meeting, including director elections, incentive plan approval, auditor ratification, and executive compensation.
NASDAQ
Ultragenyx Pharmaceutical Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Ultragenyx Pharmaceutical Inc. has released its proxy statement detailing proposals for the upcoming annual stockholders meeting, including director elections, approval of an incentive plan, and executive compensation.